Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? – InvestorsObserver

A rating of 96 puts Anavex Life Sciences Corp (AVXL) near the top of the Biotechnology industry according to InvestorsObserver. Anavex Life Sciences Corp's score of 96 means it scores higher than 96% of stocks in the industry. Anavex Life Sciences Corp also received an overall rating of 86, putting it above 86% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Anavex Life Sciences Corp (AVXL) stock is down -2.26% while the S&P 500 is up 0.9% as of 10:41 AM on Monday, Dec 28. AVXL is lower by -$0.13 from the previous closing price of $5.75 on volume of 344,926 shares. Over the past year the S&P 500 is higher by 15.99% while AVXL is up 138.14%. AVXL lost -$0.43 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Anavex Life Sciences Corp (AVXL) Stock.

Read more:
Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? - InvestorsObserver

GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity – TheNewswire.ca

Vancouver, British Columbia, Canada - TheNewswire - October 5, 2020 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and Purity Standard (CAPS) and its Fingerprint(TM) technology with the GCAC efficacy platform; with a focus on the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA$4.1 billion in 20211.

Following on from its TraceLocker announcement on September 3rd, GCAC is attracting key players in the Canadian medical cannabis space. The company's MOU with Purity-IQ is a significant endorsement of the GCAC blockchain compliance and medical efficacy data collection platform. The proposed cooperation integrates GCAC's efficacy-data with Purity-IQ's CAPS Fingerprint(TM) service, a unique genetic and chemical profile of cannabis cultivars.

GCAC's blockchain medical efficacy smartphone app immutably links a specific Purity-IQ CAPS Fingerprint(TM) cultivar directly to a consumer's anonymous efficacy attestations. This is set to revolutionize the traceability of cannabis efficacy and bring it more in line with formal medical-trial information that a traditional dispensing pharmacist would be able to reference.

Purity-IQ can uniquely identify a cultivar based on a metabolite profile using Nuclear Magnetic Resonance (NMR) and DNA chip bioinformatics. The intent is for Purity-IQ Fingerprints to be referenced by GCAC's efficacy platform to verify 'batch-to-batch' consistency in medical cannabis efficacy programs.

GCAC's CEO, Brad Moore "I have no doubt that our smartphone efficacy-data platform is an industry leader for cannabis. Bringing the Purity-IQ scientific fingerprinting of cannabis cultivars, to which our consumers will report their efficacy, really builds a picture of what works for a consumer and what doesn't. This is where medical cannabis needs to get to and, we're bringing it there!"

Brad Moore continued, "With our blockchain truths and efficacy data-sets, medical practitioners, pharmacists, cultivators and processors gain efficacy data previously only found in formal drug trials. We change that and bring the wisdom-of-the-crowd to bear for medical cannabis efficacy."

Under the agreement, GCAC contributions regarding efficacy are the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis solutions, and this is what the company believes makes GCAC one of the most exciting efficacy platforms in the cannabis and RegTech space.

1 https://www.yahoo.com/news/which-pot-stocks-will-survive-cannabis-bankruptcy-risk-131732204.html

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world's first end-to-end - from patient to regulator - medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more Company information, please visit http://www.cannappscorp.com, or review its profiles on http://www.sedar.com and on the Canadian Securities Exchange's website (www.thecse.com).

Purity-IQ IncorporatedPurity-IQ is a Canadian biotechnology company based in Mississauga, Ontario. It is committed to innovation in research and development and in the commercialization of practical and affordable validated quality assurance standards and tools, designed to further support brand product claims related to identity, authenticity, and purity. Purity-IQ focuses on commodities and inputs for the food, drug, beverage, natural health products and cannabis industries.

To schedule an interview, please contact: For more information, please contact:

Bradley Moore Corporate Communications

Chief Executive Officer Telephone: +1 (800) 409-5679

Email: bmoore@cannappscorp.com Email: info@cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

View original post here:
GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity - TheNewswire.ca

Covid-19 Update:Agricultural Biotechnology Market 2020||To Witness The Highest Growth Globally In Coming Years || MITSUI & CO., LTD., AgPlenus…

The agricultural biotechnologybusiness is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

The major players covered in the agricultural biotechnology market report areKWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Inquiry For Customize Report With Discount Athttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Insights of the Study

Global Agricultural Biotechnology Market Drivers & Restraints :

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

Read the original:
Covid-19 Update:Agricultural Biotechnology Market 2020||To Witness The Highest Growth Globally In Coming Years || MITSUI & CO., LTD., AgPlenus...

Where Does Adaptimmune Therapeutics PLC – ADR (ADAP) Stock Fall in the Biotechnology Field? – InvestorsObserver

Adaptimmune Therapeutics PLC - ADR (ADAP) is around the bottom of the Biotechnology industry according to InvestorsObserver. ADAP received an overall rating of 35, which means that it scores higher than 35 percent of all stocks. Adaptimmune Therapeutics PLC - ADR also achieved a score of 24 in the Biotechnology industry, putting it above 24 percent of Biotechnology stocks. Biotechnology is ranked 29 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is trading at $7.74 as of 1:26 PM on Thursday, Oct 15, a loss of -$0.21, or -2.7% from the previous closing price of $7.95. The stock has traded between $7.60 and $8.21 so far today. Volume today is 770,324 compared to average volume of 674,950.

Click Here to get the full Stock Score Report on Adaptimmune Therapeutics PLC - ADR (ADAP) Stock.

See original here:
Where Does Adaptimmune Therapeutics PLC - ADR (ADAP) Stock Fall in the Biotechnology Field? - InvestorsObserver

The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca’s Breakthrough Therapy Designation, 3 IPOs – Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours.

(Biotech Stocks Hitting 52-week Highs Oct. 1)

(Biotech Stocks Hitting 52-week Lows Oct. 1)

Mesoblast(NASDAQ: MESO) said the FDA issued a complete response letter to its BLA for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease. The FDA has sought the company conduct at least one additional study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.

Mesoblast said it will urgently request a Type A meeting with the FDA, which could be held within 30 days, to discuss a potential accelerated approval, with a post-approval condition for an additional study.

The FDA also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product's biologic activity, the company said.

The stock was on a T1 trading halt Thursday. In after-hours trading, the stock slumped 42.83% to $10.61.

Sanofi SA (NASDAQ: SNY) said the EMA accepted for review the marketing authorization application for avalglucosidase alfa, as a long-term enzyme replacement therapy for the treatment of patients with Pompe disease. Avalglucosidase alfa is an investigational enzyme replacement therapy, which, if approved, would offer a potential new standard of care for patients with Pompe disease.

The company expects EU approval for the therapy in the second half of 2021.

AstraZeneca plc (NASDAQ: AZN) said its Farxiga has been granted breakthrough therapy designation in the U.S. for patients with chronic kidney disease, with and without type 2 diabetes.

Metacrine Inc (NASDAQ: MTCR) announced new pharmacokinetic and pharmacodynamic data from its MET409 Phase 1b proof-of-concept clinical trial in patients with non-alcoholic steatohepatitis, or NASH, showing robust and sustained FXR activation, which is expected to be key to optimizing therapeutic benefits.

"Combined with a favorable pharmacological and tolerability profile, these results further highlight the therapeutic potential of MET409 for patients with NASH," the company said.

The company is scheduled to present these findings as two posters at the American Association for the Study of Liver Diseases' The Liver Meeting Digital Experience scheduled between Nov. 13 and 15.

The stock rose 4.17% to $10.50 in after-hours trading.

Aduro BioTech Inc (NASDAQ: ADRO) said at a special meeting of shareholders held Oct. 1, its shareholders approved its proposed merger with Chinook Therapeutics.

Following stockholder approval, the company announced a one-for-five reverse stock split. The shares will begin trading on a split-adjusted basis on Nasdaq, effective with the open of the market Friday.

The closing of the merger is anticipated to on or around Oct. 5. Following closing of the merger, the combined company will be renamed Chinook Therapeutics and trade under the trading symbol KDNY, Aduro said.

The stock was up 4.20% to $2.98 in after-hours trading.

Laboratory Corp. of America Holdings (NYSE: LH) said it received emergency use authorization from the FDA for a new, high-throughput method that uses heat and technology to extract RNA from samples collected for COVID-19 molecular testing. The advancement, the company said, will help improve the speed and efficiency of RT-PCR tests.

Xencor Inc (NASDAQ: XNCR) will present initial data from its Phase 1 dose-escalation study of tidutamab in patients with neuroendocrine tumors.

Exton, Pennsylvania-based Immunome, Inc., which uses its proprietary human memory B cell platform to discover and develop antibody therapeutics, priced its upsized initial public offering, or IPO, of 3.25 million shares of its common stock at $12, at the middle of the estimated price range of $11-$13. The offering is expected to raise gross proceeds of $39 million. The shares will begin trading on the Nasdaq under the ticker symbol IMNM.

Cancer immunotherapy company Oncorus, Inc. priced its 5.8-million-share IPO at $15 apiece, for raising gross proceeds of $87 million. The Cambridge, Massachusetts-based company had earlier estimated a price range of $14-$16. The shares will begin trading on the Nasdaq under the ticker symbol ONCR.

Watertown, Massachusetts-based C4 therapeutics, Inc. priced its upsized IPO of 9.6 million shares at $19, above the estimated price range of $16-$18. The biopharma that develops therapeutic candidates to destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases, said it expects to raise gross proceeds of $182.4 million from the offering. The shares will commence trading on the Nasdaq under the ticker symbol CCCC.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more:
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs - Benzinga

Is Evogene Ltd (EVGN) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Evogene Ltd (EVGN) is around the top of the Biotechnology industry according to InvestorsObserver. EVGN received an overall rating of 65, which means that it scores higher than 65 percent of all stocks. Evogene Ltd also achieved a score of 80 in the Biotechnology industry, putting it above 80 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Evogene Ltd (EVGN) stock is trading at $3.71 as of 2:53 PM on Friday, Oct 2, a drop of -$0.35, or -8.52% from the previous closing price of $4.05. The stock has traded between $3.55 and $3.88 so far today. Volume today is 1,164,778 compared to average volume of 1,291,117.

Click Here to get the full Stock Score Report on Evogene Ltd (EVGN) Stock.

More:
Is Evogene Ltd (EVGN) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Kaleido Biosciences Inc (KLDO) is around the top of the Biotechnology industry according to InvestorsObserver. KLDO received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Kaleido Biosciences Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 34 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Kaleido Biosciences Inc (KLDO) stock is lower by -2.62% while the S&P 500 is up 0.6% as of 1:15 PM on Thursday, Oct 1. KLDO is down -$0.29 from the previous closing price of $11.07 on volume of 311,178 shares. Over the past year the S&P 500 has risen 17.16% while KLDO is up 49.72%. KLDO lost -$2.62 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Kaleido Biosciences Inc (KLDO) Stock.

View original post here:
Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian…

Latest Research Report: Piceatannol industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Piceatannol Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/148723

Piceatannol Market competition by top manufacturers as follow:Shaanxi Fuheng (FH) BiotechnologyXian Lyphar BiotechXian Finesky TechnologicalXa Bc-BiotechXian Huisun Bio-TechRiotto BotanicalXian Biof Bio-Technology

The risingtechnology in Piceatannolmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:DrugsCosmeticsOthers

The research report summarizes companies from different industries. This Piceatannol Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Piceatannol is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/148723

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Piceatannol-Market-148723

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Continued here:
Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian...

Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D -…

Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size is expected to reach USD 4.88 billion by 2027, expanding at a CAGR of 16.6% from 2020 to 2027.

CRISPR & Cas Genes Market Report Highlights

Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human germline editing, plant genome editing, and other fields of biotechnology is expected to drive the market.

Presence of a large number of service providers that provide knockout, knock-in, gene repression, gene activation, and other cell line engineering services propel the growth of cell line engineering services. In biomedical applications, genome engineering held the largest revenue share in 2019. Adoption of gene editing techniques for human- and non-human-based genomic engineering is one of the key factors that drive the segment.

The molecular scissor can facilitate the detection of viruses, allowing the development of cost-effective, robust, and rapid point-of-care diagnostics. It allows the detection of viruses at a level of molecular concentration that researchers rarely assess. Sherlock Bioscience estimated that a CRISPR-powered diagnostic test would be available in the future at a reasonable price. In recent times, the most important innovation has been the development of a test for COVID-19.

In March 2020, Mesa Biotech announced FDA authorization for its Accula device, a hand-held COVID-19 diagnostic test. Similarly, in April 2020, CSIR lab announced the development of a paper-strip test for Covid-19 that uses CRISPR-Cas9 to target and identifies the genomic sequences of the virus. Unlike the PCR tests, this test is available at a very low price, USD 6.59 (INR 1 = USD 0.013). Therefore, such initiatives are expected to encourage other players to leverage this crisis and launch novel products.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary2.1 Market Snapshot, 2019 (USD Million)

Chapter 3 Crispr And Cas Genes Market Variables, Trends & Scope3.1 Market Trends & Outlook3.2 Market Segmentation & Scope3.3 Market Lineage Outlook3.3.1 Parent Market Outlook3.3.2 Related/Ancillary Market Outlook3.4 Crispr And Cas Genes: Patent Landscape3.4.1 By End - Use Settings3.4.2 By Variants Of Crispr Enzymes3.5 Penetration And Growth Prospect Mapping, By Biomedical Applications, 20193.6 Potential Threat Analysis To Crispr Technology3.6.1 Variations In The Crispr System3.7 Investors Perspective Analysis3.8 User Perspective Analysis3.9 Technology Mapping In Crispr Genome Editing Workflow3.10 Developments And Innovations For Analysis Of Off - Target Effects3.11 Crispr Technologies: Clinical Penetration3.11.1 Human Therapeutics3.11.2 Diagnostics3.11.3 Microbiome Research And Drug Resistance3.11.4 Animal Disease Models

Chapter 4 Industry Outlook4.1 Market Dynamics4.1.1 Market Driver Analysis4.1.1.1 Rising Adoption In Diverse Fields Of Biotechnology4.1.1.1.1 Epigenetics4.1.1.1.2 Medicine4.1.1.1.3 Human Germline Editing4.1.1.1.4 Tool For Qualitative And Quantitative Plant Genome Editing4.1.1.2 Technological Advancements In Crispr4.1.1.3 Introduction Of Anti - Crispr Protein4.1.1.4 Ongoing Competition For Crispr Commercialization4.1.2 Market Restraint Analysis4.1.2.1 Off - Target Effects Of Crispr Technology4.1.2.2 Intellectual Property Disputes Pertaining To Cas4.1.2.3 Ethical Concerns And Implications With Respect To Human Genome Editing4.1.3 Market Opportunity Analysis4.1.3.1 Expanding Gene & Cell Therapy Area4.1.3.2 Government Fund In Genomic R&D4.1.4 Market Challenge Analysis4.1.4.1 Risks Pertaining To The Usage Of Genetically Modified Food4.2 Policy Making & Regulation For Genetic Modification Using Crispr4.3 Porter's Five Forces Analysis4.4 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)

Chapter 5 Competitive Landscape5.1 Companies (Diagnostic & Drug Developers) Leveraging Gene Editing Technologies5.2 Major Deals & Strategic Alliances Analysis5.3 Market Entry Strategies5.3.1 Crispr Therapeutics: Business Translation5.3.2 Crispr Gene Editing Companies' Toolboxes5.4 Crispr And Cas Genes Market: Pipeline Analysis5.4.1 Editas Medicine5.4.2 Intellia Therapeutics, Inc.5.4.3 Crispr Therapeutics5.4.4 Caribou Biosciences, Inc.5.4.5 Egenesis5.4.6 Beam Therapeutics5.4.7 Ksq Therapeutics5.4.8 Cibus

Chapter 6 Product & Service Business Analysis6.1 Crispr And Cas Genes Market: Product & Service Movement Analysis6.2 By Product6.2.1 Global Crispr And Cas Genes Products Market, 2016 - 2027 (USD Million)6.2.2 Kits & Enzymes6.2.3 Global Crispr And Cas Genes Kits And Enzymes Market, 2016 - 2027 (USD Million)6.2.3.1 Vector - Based Cas96.2.3.2 Dna - Free Cas96.2.4 Libraries6.2.5 Design Tools6.2.6 Antibodies6.2.7 Others6.3 By Service6.3.1 Global Crispr And Cas Genes Service Market, 2016 - 2027 (USD Million)6.3.2 Cell Line Engineering6.3.3 Grna Design6.3.4 Microbial Gene Editing6.3.5 Dna Synthesis

Chapter 7 Application Business Analysis7.1 Crispr And Cas Genes Market: Application Movement Analysis7.2 Biomedical7.2.1 Global Crispr And Cas Genes Market For Biomedical, 2016 - 2027 (USD Million)7.2.2 Genome Engineering7.2.3 Disease Model Studies7.2.4 Functional Genomics7.2.5 Epigenetics7.2.6 Others7.3 Agriculture

Chapter 8 End - Use Business Analysis8.1 Crispr And Cas Genes Market: End - Use Movement Analysis8.1.1 Biotechnology & Pharmaceutical Companies8.1.2 Academics & Government Research Institutes8.1.3 Contract Research Organizations (Cros)

Chapter 9 Regional Business Analysis

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/lypwvp

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D -...

Separation Systems for Commercial Biotechnology Market: Rising Research and Development Activities to Encourage Market Growth – BioSpace

New technologies are emerging within the separation systems relating to chromatographic devices and consumables biotechnology. This is attracting many new players in the market. The emergence of technology is behind the growth of the separation systems for commercial biotechnology.

Read Report Overview - https://www.transparencymarketresearch.com/separation-systems-commercial-biotechnology-market.html

The key players within the market are: Merck KGaA, Thermo Fisher Scientific, Inc., Waters Corporation, Danaher Corporation, GE Healthcare, Dickinson and Company, and Becton. Of these, Danaher Corporation is dominating the market on account of its advanced technological innovations, states Transparency Market Research (TMR).

According to the report by TMR, the separation systems for commercial biotechnology market is expected to grow steadily on account of various companies being keen to explore this sector. As per the report, the market will be worth US$19,227.8 mn by the end of 2023. On the basis of application, the life sciences research and diagnostics segment is likely to continue to lead.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2104

Europe is anticipated to lead in the market in terms of geography. The region is home to some of the biggest well-established firms which are involved in developing advanced chromatography technologies and solutions, which contributes to the growth of separation systems for commercial biotechnology market.

Increasing Investments in R&D Boosting Markets Growth

One of the key factors boosting the growth of the global separation systems for commercial biotechnology market is the growing investments in research and development. The participation by government agencies and the increasing number of biotech companies are other factors helping the market to grow. The advancements and the subsequent increase in the demand for microarray technology is also contributing to the growth of the separation systems for commercial biotechnology market.

Request for Analysis of COVID-19 Impact on Separation Systems for Commercial Biotechnology Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2104

Lab Automation to Aid Markets Growth

The dropping costs of developing new technology and experimenting on account of lab automation will also go a long way towards the growth of the separation systems for commercial biotechnology. Thanks to lab automation, samples are processed at relatively low cost and is contributing extensively to the growth of the separation systems for commercial biotechnology market.

Across geographical regions, several conferences are held so as to spread the awareness level and educate organizations regarding the latest and emerging developments. The other reason for holding these conferences are for investments, proposing grants, mergers, and asking for funds for experimentation.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2104

Increasing Interest by Pharmaceutical Companies to Push Markets Growth

Separation systems for biotechnology is implemented across biological products such as proteins, nucleic acid, and cell cultures and therefore holds an important status within the biotechnology and pharmaceutical Industries. The increasing interest by pharmaceutical products across the globe is behind the rising demand for separation systems for commercial biotechnology.

Buy Separation Systems for Commercial Biotechnology Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=2104&ltype=S

Extensive research is held in the field of Life Sciences such as bio separation procedures are expected to create a strong impact for the separation systems for commercial biotechnology market.

Browse More Trending Reports by Transparency Market Research:

Meniscus Repair Systems Market: https://www.transparencymarketresearch.com/meniscus-repair-systems-market.html

Hazmat Suits Market: https://www.transparencymarketresearch.com/hazmat-suits-market.html

Stroke Post Processing Software Market: https://www.transparencymarketresearch.com/stroke-post-processing-software-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

View post:
Separation Systems for Commercial Biotechnology Market: Rising Research and Development Activities to Encourage Market Growth - BioSpace

EPA Proposes to Allow Certain Uses of Biotechnology in Development of Plant-Incorporated Protectants – JD Supra

Key Takeaways

In a new rule proposed September 1, the U.S. Environmental Protection Agency (EPA) announced its intent to streamline the regulatory requirements for certain plant-incorporated protectants (PIPs)regulated pesticidal substances produced by plants, as well as the genetic material necessary for the plant to produce those substances. Currently, only PIPs developed through conventional breeding are exempt from EPAs pesticide registration requirements. All other PIPs, including those developed using biotechnology, must be registered by EPA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and must obtain a tolerance or exemption from tolerance for pesticide food residues under the Federal Food, Drug, and Cosmetic Act (FFDCA) prior to their distribution or sale.

EPAs proposed rule would expand this longstanding exemption to now include PIPs developed using biotechnology, as long as the new plant-produced pesticidal substance can already be found in plants that are sexually compatible with the recipient plant and EPAs proposed exemption criteria are otherwise met. Developers would be required to submit a self-determination letter or otherwise seek affirmative confirmation from EPA to utilize the exemption.

According to EPA, the proposal is intended to make the regulatory process more efficient and increase the availability of these innovative technologies, while continuing to ensure adequate safety. The proposed rule implements Executive Order 13874, 84 Fed. Reg. 27899 (June 11, 2019), Modernizing the Regulatory Framework for Agricultural Biotechnology Products, which directed EPA and other federal agencies to exempt low-risk products of agricultural biotechnology from undue regulation as permitted by law and grounded in scientific evidence. To learn more about this executive order, see our news alert here.

As of September 2, 2020, the proposed rule is still in pre-publication. EPA will accept comments from stakeholders and the public for 60 days following publication of the proposed rule in the Federal Register.

FIFRA prohibits the distribution or sale of any pesticide in the United States that is not first approved by and registered with EPA. A pesticide is defined broadly to include any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest. 7 U.S.C. 136(u). PIPs refer to pesticidal substances produced by a plant itself, along with the genetic material that allows the plant to do so. As pesticides under FIFRA, PIPs require registration before they may be distributed or sold. Over the last several decades, for example, EPA has registered dozens of insecticidal Bacillus thuringiensis (Bt) proteins introduced into corn, cotton, soybean, and other plants. Once these PIPs have been incorporated, the plants themselves are able to manufacture the pesticidal protein to control insects that feed on them. Although EPA regulates PIPs and their genetic material, it does not regulate the individual plants producing or containing the PIP.

As with conventional chemical pesticides, an applicant for a PIP registration must submit sufficient data to EPA to demonstrate that the pesticide at issue will present no unreasonable adverse effects to humans or the environment when used as intended. Moreover, under the FFDCA, EPA must also establish a tolerance (or exemption from a tolerance) before allowing any use of a pesticide that may result in residues in or on foods. Generating the extensive data necessary to support EPA registration and establishment of a tolerance can substantially increase the level of time and resources required to bring a new pesticide product to market.

In 2001, EPA promulgated regulations exempting certain PIPs from FIFRAs registration requirement if (1) the genetic material that encodes the pesticidal substance is from a plant that is sexually compatible with the recipient plant, and (2) that genetic material is not derived from a source that is not sexually compatible with the recipient plant. EPA further defined the term sexually compatible to include only conventional breeding, which has historically excluded any genetically engineered PIPs from the exemptions scope.

EPAs proposed rule would expand the existing exemption to include not only PIPs developed through conventional breeding but also certain PIPs developed using biotechnology. To accomplish this, EPA is proposing to add a new exemption to the Agencys regulations found at 40 CFR part 174, as well as to expand the existing definition of sexually compatible. To qualify for the new proposed exemption, a PIP developed using biotechnology will qualify for the new exemption if it:

PIP developers would be required to submit either a letter of self-determination or a request for EPA confirmation that a PIP based on a sexually compatible plant but created through biotechnology meets the criteria for exemption. Among other considerations, developers will need to weigh the potential benefits of relying on a self-determination letter, including the potential ability to bring a product to market more quickly, against the risk of a subsequent Agency determination that their PIP does not meet the new exemptions criteria.

Products exempt from registration under the proposed rule would also remain exempt from regulation under the recently revised USDA regulations at 7 CFR part 340, restricting the movement of certain genetically engineered organisms.

[View source.]

Read more from the original source:
EPA Proposes to Allow Certain Uses of Biotechnology in Development of Plant-Incorporated Protectants - JD Supra

Drug Intermediate Market: Fast growing biotechnology and life sciences sectors is expected to drive the growth – BioSpace

Drug intermediates are the drugs used as raw materials for the production of bulk drugs, or they can refer to a material produced during synthesis of an API that must undergo further molecular change or processing before it becomes an API. Drug intermediates are hygienically formulated using high grade raw materials and they are used in the pharmaceutical and cosmetic industry. Pharmaceutical companies use drugs intermediates for research and development purposes. Pharmaceutical intermediates, veterinary drug intermediates, and bulk drug intermediates are various types of drug intermediates. The global drug intermediate market is expected to grow at a high rate owing to rising research and development activity globally.

Read Report Overview - https://www.transparencymarketresearch.com/drug-intermediate-market.html

The market of drug intermediates is segmented on the basis of type of intermediate, end user, and by region. On the basis of type of intermediate, the market is segmented into two main types, API intermediate, and advanced intermediate. API or active pharmaceutical ingredient intermediates are the raw materials or raw drugs responsible for therapeutic action. They are the active ingredients which are later converted into various forms such as tablets, capsules, suspensions etc. API acts as a drug itself. Advanced intermediates are advanced forms of drug intermediates. Advanced intermediate drugs are used to perform drug interaction activity which formed in new chemical products. Capecitabine intermediates, imatinib intermediates, lenalidomide intermediates, pemetrexed intermediates, nilotinib intermediates, temozolamide intermediates, gemcitabine intermediates, afatinib intermediates, pazopanib intermediates, and ibrutinib intermediates are few examples of drug intermediates.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31493

On the basis of end user, the global drug intermediate market is segmented into pharmaceutical industry, biotechnology industry, and chemical industry. Drug intermediates are available in various forms such as moderate quality drug intermediates, high quality intermediates, and premium quality intermediates. The high and premium quality drug intermediates are used mainly for research purposes. There has been an ever increasing demand for drug intermediates in the global market due to the fast growing biotechnology and life sciences sectors, along with rising adoption and increasing application of drug intermediates in research fields. Pharmaceutical companies and biotechnology companies, along with research companies around the world have shown growing focus toward R&D in drug discovery and development, New methods and technologies in the equipment for synthesizing drug intermediate with manufacturers providing numerous customizations in the synthesized drugs, has widened the scope of applications and led to increasing demand for drug intermediate in the global market.

Request for Analysis of COVID-19 Impact on Drug Intermediate Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31493

By geography, the market for drug intermediates is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific leads the drug intermediate market owing to rising pharmaceutical and life sciences industry in the region especially in emerging markets in countries such as India and China. Europe is the second leading market for drug intermediates due to development and expansion of more efficient and advanced technologies. The Asia Pacific drug intermediate market is also anticipated to expand at an increasing rate owing to increasing healthcare spending, adoption of western lifestyle, and growth in research and development. Asia Pacific is the fastest growing region for the drug intermediate market as several players have invested in the development and manufacturing of drug intermediates. These factors are expected to drive the market growth of drug intermediates during the forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=31493

Key players in the global Drug Intermediate market are Ami Lifesciences, Accrete Pharmaceuticals Pvt. Ltd, A. B. Enterprises, Ramdev Chemicals Pvt. Ltd., Clearsynth, Aarti Drugs Ltd., Synpure Labs, and Karvy Therapeutics Pvt. Ltd among others. The rising competition in the pharmaceutical and biotechnology industry for outsourcing of drug intermediates and manufacturing of drug intermediates is expected to boost the growth of the global drug intermediate market during the forecast period.

Pre Book Drug Intermediate Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=31493&ltype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse More Trending Reports by Transparency Market Research:

Lumbar Stenosis Treatment Market: https://www.transparencymarketresearch.com/lumbar-stenosis-treatment-market.html

Intracranial Stenosis Treatment Market: https://www.transparencymarketresearch.com/intracranial-stenosis-treatment-market.html

Plastic Bandages Market: https://www.transparencymarketresearch.com/plastic-bandages-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See the original post here:
Drug Intermediate Market: Fast growing biotechnology and life sciences sectors is expected to drive the growth - BioSpace

Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? – InvestorsObserver

BELLUS Health Inc (BLU) is around the middle of the Biotechnology industry according to InvestorsObserver. BLU received an overall rating of 43, which means that it scores higher than 43 percent of all stocks. BELLUS Health Inc also achieved a score of 43 in the Biotechnology industry, putting it above 43 percent of Biotechnology stocks. Biotechnology is ranked 36 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

BELLUS Health Inc (BLU) stock is unchanged 0% while the S&P 500 is down -0.27% as of 1:21 PM on Friday, Nov 20. BLU is flat $0.00 from the previous closing price of $3.18 on volume of 1,380,191 shares. Over the past year the S&P 500 has gained 15.10% while BLU is down -53.10%. BLU lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BELLUS Health Inc (BLU) Stock.

Continued here:
Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? - InvestorsObserver

After Years of Neglect, Algae Biotechnology Makes a… – Labiotech.eu

Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches.

In the center of Paris, just across from Marie Curies old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. [Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, he told me.

The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no-brainer. Algae grow biomass literally out of thin air, only needing water, carbon dioxide, and inorganic nutrients. Many grow on seawater and in lands not suitable for agriculture.

Today, we are managing quite well in transforming algae. I would thus not consider it particularly difficult, says Crozet, pointing out that, nowadays, obtaining a new strain of algae using genetic engineering takes just weeks. So, technically, they should be able to effectively replace bacteria and yeast, which generally require more complex growth facilities as well as the input of a sugar source in order to be able to generate any product.

However, algae have historically not been considered a good alternative to yeast and bacteria because of their slower growth rate. In addition, the crash of many algae biofuel companies about a decade ago dealt a blow to the field that it still has trouble recovering from.

The early 2010s saw several startups forming to produce biofuels, mainly in the US. Many claimed to be close to offering algal biofuel at competitive market prices. Sapphire Energy, Solazyme, and Algenol, among others, received significant public and private investments and built up high expectations. But due to technological challenges and the drop in oil prices between 2015 and 2016, no product became commercially viable and these businesses either went bankrupt or had to radically change their focus.

The [challenge] of algae and cyanobacteria comes down to their slow growth and the cost of production, says Hugh Goold, Research Scientist at the NSW Department of Primary Industries, Australia. According to Goold, the resources required to keep photosynthesis going is very high, meaning they dont replicate as quickly as the bacteria and yeast commonly used in biotech applications.

Bacteria and yeast have been optimized for many years in biotech applications such as producing commodity chemicals as well as high-value compounds such as pharmaceuticals, meaning that photosynthetic organisms can no longer compete with these applications. Investors have to know that you are going to produce a product cheaper than other people can. It isnt worthwhile to produce something in algae instead of E. coli just because, said Goold.

Despite this challenge, algae and cyanobacteria have started to get interest from new market niches where they could offer key advantages over traditional bioproduction methods.

Microalgae capture sunlight using pigments of vibrant colors, such as chlorophylls, carotenoids, and phycocyanin. In particular, the algae spirulina and chlorella found their way to the market a long time ago as food supplements and food colorants. Algae are also an excellent source of protein, which opens up a lot of opportunities in the production of meat analogs and vegan food in general.

Unilever, a massive producer of food and other consumer goods, has seen the nutritional potential of microalgae, partnering with UK-based company Algenuity in July. Algae are a source of high-quality plant-based protein, said Manfred Aben, Vice President of Science & Technology at Unilever. These products will appeal to a variety of consumers; for vegans and vegetarians but also for flexitarians and meat-eaters looking to reduce their consumption of animal products.

Within the food and beverage sector, the opportunities for microalgae-based ingredients are strong and tangible, explained Andrew Spicer, CEO of Algenuity. We do anticipate applications for microalgae-based ingredients in markets other than food and beverages where similar drivers around sustainability, plant-based, and natural sources of ingredients are equally strong.

Last year, the Dutch food and biochemical company Corbion announced a similar partnership with Nestl, signaling that big players in the food industry are starting to increasingly recognize the potential value of algae products. Other companies gaining traction in the field are Algama in France seeking to provide meat alternatives, and AlgaEnergy in Spain producing food and feed as well as cosmetics and fertilizers from algae.

In 2011, Renana Krebs graduated from the Shenkar College of Engineering, Design, and Art in Tel Aviv with a degree in fashion. While working for fashion brands, she realized the huge impact the industry has on the environment. Clothes and textiles manufacturing accounts for 10% of global carbon emissions and 20% of wastewater. Looking for alternative solutions, Krebs teamed up with her father and founded Algalife, a German-Israeli company offering algae-based fibers and textiles.

Algalife stands for a better planet and a better fashion industry. We provide and enable the opportunity for everyone to make better choices, for a healthy, sustainable well-being, Krebs told me. The company collaborates with fashion brands that are willing to learn and adjust their practices to include the green fibers, and even pay more for sustainable solutions.

Renana Krebs considers algae as one of the most influential resources for sustainable development, and notes that she gets requests from companies outside the fashion industry.

Over in San Diego, California, the startup Algenesis has been using algae oil as a replacement for petroleum. The two first products launched by the startup, whose founders are all surfers, are a surfboard and flip flops made from an algal biopolymer that is biodegradable.

In addition to fashion, algae can also be used to produce sustainable alternatives to everyday petrochemical products. For example, the startup Living Ink, in the US, aims to provide an eco-friendly alternative to printing ink using cyanobacteria.

After some initial hiccups, algae seem to be finding their way into the market. The new generation of startups in this field focus more on business-to-business relationships but build their branding around customers demand for environmentally friendly products.

It seems clear that cyanobacteria and algae will not replace bacteria and yeast as fermentation organisms in traditional applications. However, they have unique characteristics and a potential waiting to be unlocked by more research and daring business ideas. I cannot see limitations to what can be done with algae, but our own imagination, noted Crozet.

Cover illustration by Elena Resko, pictures courtesy of AlgaEnergy and AlgaLife

Read the original here:
After Years of Neglect, Algae Biotechnology Makes a... - Labiotech.eu

Gear up for the change! Unity Biotechnology Inc. (UBX) has hit the volume of 830077 – The InvestChronicle

Lets start up with the current stock price of Unity Biotechnology Inc. (UBX), which is $5.97 to be very precise. The Stock rose vividly during the last session to $6.55 after opening rate of $5.74 while the lowest price it went was recorded $5.74 before closing at $6.36.

Recently in News on November 4, 2020, UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates. UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020. You can read further details here

Unity Biotechnology Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $15.44 on 08/10/20, with the lowest value was $2.72 for the same time period, recorded on 08/24/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Unity Biotechnology Inc. shares are logging -61.37% during the 52-week period from high price, and 119.30% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $2.72 and $15.44.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 830077 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Unity Biotechnology Inc. (UBX) recorded performance in the market was -11.79%, having the revenues showcasing 110.60% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 298.98M, as it employees total of 76 workers.

During the last month, 5 analysts gave the Unity Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.37, with a change in the price was noted -1.83. In a similar fashion, Unity Biotechnology Inc. posted a movement of -23.22% for the period of last 100 days, recording 1,269,373 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for UBX is recording 0.25 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.25.

Raw Stochastic average of Unity Biotechnology Inc. in the period of last 50 days is set at 80.52%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.41%. In the last 20 days, the companys Stochastic %K was 88.45% and its Stochastic %D was recorded 90.89%.

Lets take a glance in the erstwhile performances of Unity Biotechnology Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -11.79%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -32.20%, alongside a downfall of -12.88% for the period of the last 12 months. The shares increased approximately by 34.46% in the 7-day charts and went down by 59.80% in the period of the last 30 days. Common stock shares were driven by 110.60% during last recorded quarter.

Original post:
Gear up for the change! Unity Biotechnology Inc. (UBX) has hit the volume of 830077 - The InvestChronicle

Its been a strong year for International Biotechnology Trust – QuotedData

International Biotechnology Trusts (IBT) has reported full-year results, to 31 August 2020.IBTs NAV per share and share price returned 22.4% and 18.7%, whilst the NASDAQ Biotechnology index (NBI) returned 20.6% (to 31 August 2020) and the FTSE All-Share index returned -12.6% (to 28 August 2020).

The table below summarises IBTs cumulative total return performance over the past five years.

As at 31 August 2020, for financial reporting purposes, the quoted portfolio represented 94.0% of IBTs NAV. The quoted portfolio returned 26.4%.In 2016, the board took the decision that the company would no longer make any new investment directly in unquoted investments but instead will allow investors access to the unquoted market through a diversified venture capital fund.IBTs investment in SV Fund VI had a fair value gain of 2.9m (on a sterling-adjusted basis), representing a total return of 14.6% on the funds portfolio.

IBTs manager noted the following: M&A activity continues to be a key driver of performance for the biotechnology sector despite the impact of COVID-19. During the year ended 31 August 2020, the Company has been well placed to take advantage of this M&A activity to generate returns for its investors. Our view is that many companies within the biotechnology sector are currently undervalued, a sentiment we believe is supported by the increased level of M&A activity within the sector.

In November 2019, Novartis acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7bn, which represented a premium of 41%. The sale completed in January 2020. At the time of the announcement, 0.7% of the Companys NAV was invested in The Medicines Company. The Companys NAV benefited from the announcement and the Company sold out of its investment shortly thereafter, therefore crystallising this gain.

In December 2019, Merck acquired ArQule, a biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, for $2.7bn, representing a 107% premium over the share price. The sale was completed in January 2020. The Company held positions in both Merck (2.2% of NAV) and ArQule (0.1% of NAV) at the time of the announcement and the Companys NAV benefited from this deal.

The second half of the financial year, specifically the month of August, was particularly successful for M&A activity within the biotechnology sector.

Sanofi announced its intention to acquire Principia Biopharma, a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, for approximately $3.7bn, representing a premium of 70%. At the time of the announcement, Principia comprised 0.6% of the Companys NAV and the transaction is expected to complete in the fourth quarter of 2020.

Johnson & Johnson announced its intention to acquire Momenta Pharmaceuticals, a company that discovers and develops novel therapies for immune-mediated diseases, for a cash consideration of $6.5bn, representing a premium of 70% over the share price. Momenta comprised 0.3% of the Companys NAV at the time of the announcement.

This pace of M&A is showing no indications of slowing down. Since the year-end, Gilead Sciences has announced that it has entered a deal to acquire Immunomedics for approximately $21bn, which represented a premium of 108% to the share price. The Companys NAV benefited from this announcement as the Company had 3.7% of its NAV invested in Immunomedics and 5.3% of its NAV invested in Gilead Sciences.

In October 2020, Bristol Myers Squibb announced its intention to acquire MyoKardia for a cash consideration of $13.1bn, representing a 61% premium to the share price. At the time of the announcement, the Company had 2.3% of its NAV invested in MyoKardia.

The manager added: Innovation remains one of the core drivers of the biotechnology sectors performance. This, in conjunction with the positive developments made in the FDAs development and review process, also contributed to the biotechnology sectors relative outperformance during the financial year. As at 31 August 2020, there were over 25,000 ongoing clinical studies, with the number of studies expected to exceed the previous calendar years by the end of 2020. It is expected that this pace of innovation and efficiency displayed by the FDA will continue its forward momentum and will be translated into sales and earnings for the biotechnology sector going forward.

The US Presidential Election and any associated potential drug pricing and healthcare reforms have historically caused volatility within the biotechnology and healthcare sectors. Former Vice President Joe Bidens formal election as the Democratic Candidate means that the more disruptiveMedicare for Allpolicy changes, favoured by his opponents Elizabeth Warren and Bernie Sanders, are now seen as highly unlikely. The risk to the biotechnology sector has, therefore, lessened, with Biden more generally viewed as a centrist candidate and President Donald Trump considered relatively supportive of the biotechnology sector.

With the fundamentals of the biotechnology sector intact, we are optimistic about the future of the Company and the biotechnology sector, more generally.

IBT:Its been a strong year for International Biotechnology Trust

previous story|next story

More:
Its been a strong year for International Biotechnology Trust - QuotedData

Is United Therapeutics Corporation (UTHR) the Top Pick in the Biotechnology Industry? – InvestorsObserver

The 50 rating InvestorsObserver gives to United Therapeutics Corporation (UTHR) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 53 percent of stocks in the Biotechnology industry, UTHRs 50 overall rating means the stock scores better than 50 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

United Therapeutics Corporation (UTHR) stock is up 4.94% while the S&P 500 is lower by -3.05% as of 11:13 AM on Wednesday, Oct 28. UTHR is higher by $6.10 from the previous closing price of $123.40 on volume of 413,382 shares. Over the past year the S&P 500 has gained 8.25% while UTHR is higher by 48.87%. UTHR earned $9.74 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 13.27.

Click Here to get the full Stock Score Report on United Therapeutics Corporation (UTHR) Stock.

Read more from the original source:
Is United Therapeutics Corporation (UTHR) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Verdant Technologies announces launch into biotechnology industry – Produce Blue Book

ST. PAUL, MN Verdant Technologies announces its commercial launch into the biotechnology industry, bringing innovative 1-MCP solutions to market designed to help the produce and floral industries deliver fresher, longer-lasting products in a one-step application process.

Verdant Technologies, an affiliate of privately-held Holiday Companies, operates on a foundation of continuous innovation, uncompromising quality and a belief that their technology can significantly impact produce and floral value, reduce waste and increase the reach of traditional supply chains.

The Verdant team strives to bring technologies to market that make a meaningful impact to our worlds health and well-being through the global food system. Everything we do, from research to production, is done with the purpose of delivering nourishment to more people in more places, said Gordon Robertson, Chief Revenue and Marketing Officer for Verdant Technologies.

Verdant Technologies has been in operation for over twenty years with a team of scientific minds and experienced leaders working in tandem to develop a portfolio of worldwide patent products. The companys solutions allow producers to safely delay the ripening process and extend the shelf life of fruits, vegetables and flowers while reducing greenhouse gas emissions.

We have developed technologies protected by patents and trade secrets focused on the extension of produce and floral life and reduction of waste. Our solutions serve the agricultural and floral communities with unmatched storability, portability and ease of operational integration. We believe now is the time to introduce Verdant Technologies and our solutions to the world, said Jon Fobes, President of Verdant Technologies.

Verdant Technologies products contain the active ingredient 1-methylcyclopropene (1-MCP), which is applied to sheets, stickers and labels for use in a variety of packaging materials in a simple one-step application. Testing shows the use of Verdant technology to increase shelf life of produce by an average of 50%.

HarvestHold by Verdant Technologies, the sheet form of Verdants 1-MCP solutions, will be first of the companys patented products available in the global marketplace. As floral and produce products are harvested, growers and packers will begin the application process by inserting a sheet of HarvestHold into the packaging from which 1-MCP is released. Growers, packers and retailers can expect to see the first HarvestHold products available in Q1 2021.

Verdant develops advanced technology solutions reflective of the companys passions for improved nutrition, reducing food and floral waste and impacting the global food system through continuous innovation. HarvestHold is one of our answers to improving negative environmental issues and profit margins throughout the supply chain process, said Fobes.

In addition to its commitment to bringing innovative life-extension technologies to market, Verdant Technologies is driven by its partnerships with customers, working together to enhance profitability while maximizing productivity and solving perishability issues in the supply chain.

Everyone in the industry wants to accomplish the same thing provide nourishment to the global community. At Verdant Technologies, we work towards the same goal with innovative products unmatched in ease of application and reliability. Our customers and investors can expect to be equal partners in our mission to bring nourishment to more people in more places. Everyone in the supply chain is essential to our mission. Through our commitment to collaboration and purpose-driven work, we will be successful and continue to find new solutions to offer the industry, said Robertson.

About Verdant Technologies

Verdant Technologies is an emerging leader to the biotechnology industry, offering HarvestHold product life extension technology for floral and produce products. Verdant Technologies and its partners work hand-in-hand to reduce negative environmental impacts while delivering fresher, more nutritious produce and enhanced florals to more people in more places. Verdant Technologies has corporate offices in St. Paul, Minn.

For more information, visit http://www.verdant-tech.com.

Read more from the original source:
Verdant Technologies announces launch into biotechnology industry - Produce Blue Book

Surface functionalization: A tool for biotechnology and health sectors – Open Access Government

Case study 1: Nanoparticles as Oxygen Scavengers for food-packaging

Partners: University of Minho and International Iberian Nanotechnology Laboratory

Funding: Portuguese Foundation for Science and Technology (FCT) in the framework of the project NANOXYPACK co-financed via FEDER (PT2020) POCI-01-0145-FEDER-030789.

The development of oxygen-sensitive and detecting materials is one of the main aims in the packaging industry, as even a 2% residual oxygen concentration may alter food organoleptic properties. The presence of oxygen in the packaging, as well as the permeation of oxygen during storage, is then avoided by using oxygen scavenging materials and controlled by using packaging materials with low permeability to gases.

This project addresses the development of a new generation of active and intelligent packaging film for foods through the dispersion of nano-sized multifunctional particles (Figure 1) incorporated by magnetron sputtering onto a bio-polymeric matrix.The enhanced oxygen absorption capacity, antimicrobial properties and changes in colour as a function of oxygen absorption provide the packagingmaterial with the multifunctional characteristics required to enlarge the shelf-life of the food.

Partners: University of Minho and University of Porto and DENTAL VERDE CLNICA MDICA E DENTRIA, LDA

Funding: Portuguese Foundation for Science and Technology (FCT) in the framework of the HEALTHYDENT (co-financed via FEDER (PT2020) POCI-01-0145-FEDER-030708

The HEALTHYDENT project develops a new concept of dental implants. A novel surface with graded functional treatments will give a solution for the main problems of dental implants used nowadays: Poor bioactivity that delays osseintegration, and periimplantitis, an inflammatory disease due to bacterial infection.

The strategy to achieve this novel design was accomplished in two main steps. As first step, tantalum surface functionalization was carried out by micro-arc oxidation (also called plasma electrolytic oxidation, an electrochemical process derived from anodization) to create a porous tantalum oxide (Ta2O5) surface enriched with calcium and phosphorous in order to mimic the morphology and chemical composition of the bone tissue (Figure 2-A). Secondly, this enriched porous Ta2O5 surface was doped with zinc (Zn) nanoparticles (Figure 2-B), by DC magneton sputtering technique providing the antibacterial ability. As it is crucial to guarantee the balance between the non-toxicity of the Zn nanoparticles and the bacterial inhibition, an additional carbon layer was deposited after Zn nanoparticles deposition (Figure 2- C, D and E).

The biological response of the modified surface was evaluated, and it was observed that the surface functionalization did not show toxicity, as shown by the MTT assay for the sample with Zn nanoparticles and the sample with Zn nanoparticles and the carbon layer (Figure 3-A and B, respectively) and by the cells adhesion and proliferation in both surfaces (Figure 3- C and D, respectively). It is important highlight that the sample with the Zn nanoparticles revealed a more efficient ability to inhibit the bacteria adhesion than the surface functionalization with the Zn nanoparticles and the carbon layer, Figure 3-E and F, respectively.

Partners: University of Minho, University of Coimbra and ICC-Indstrias e Comrcio de Calado S.A

Funding: Science DiabetICC Footwear POCI-01-0247-FEDER-039784

Science DiabetICC Footwear project proposes the development of a new typology of footwear oriented to the segments of therapeutic footwear targeting the clinical condition of Diabetic Foot (DF). The solution consists of components of the footwear and a removable insole, adding the ability to reduce the risk of ulcer-associated infections. In this context, at the insoles level, antimicrobial coatings deposited by magnetron sputtering were developed, aiming to prevent the occurrence of infections resulting from DF.

In vitro antimicrobial activity was assessed using a yeast Candida parapsilosis and a bacterium Staphylococcus epidermidis commonly found on the skin. Different coatings were tested, and the AgO-0.25 coating was the one that showed the best results, it has a greater halo around the sample (transparent zone indicating the absence of microorganisms) as can be seen in figure 4 and through the SEM images obtained after the test, the original leather contains microorganisms, contrary to the one coated with AgO.

*Please note: This is a commercial profile

Editor's Recommended Articles

See the article here:
Surface functionalization: A tool for biotechnology and health sectors - Open Access Government

Impact Of Covid-19 on Agricultural Biotechnology Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – Crypto Daily

Agricultural Biotechnology Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Agricultural Biotechnology market is a compilation of the market of Agricultural Biotechnology broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Agricultural Biotechnology industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Agricultural Biotechnology industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Agricultural Biotechnology Market report @ https://hongchunresearch.com/request-a-sample/64512

The following manufacturers are covered:SyngentaDuPontMonsantoADAMA Agricultural SolutionsBASFBayer CropScienceCertis USADow AgroSciencesMycogen SeedPerformance PlantsKWS SAATEvogeneRubiconVilmorinGlobal Bio-chem Technology

Access this report Agricultural Biotechnology Market @ https://hongchunresearch.com/report/worldwide-agricultural-biotechnology-market-2019-64512

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeMolecular MarkersVaccinesGenetic EngineeringTissue CultureMolecular DiagnosticsOther

Segment by ApplicationTransgenic Crops/SeedsBiopesticidesOther

For a global outreach, the Agricultural Biotechnology study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Agricultural Biotechnology Market @ https://hongchunresearch.com/check-discount/64512

Major Point of TOC:

Chapter One: Agricultural Biotechnology Market Overview

Chapter Two: Global Agricultural Biotechnology Market Competition by Manufacturers

Chapter Three: Global Agricultural Biotechnology Production Market Share by Regions

Chapter Four: Global Agricultural Biotechnology Consumption by Regions

Chapter Five: Global Agricultural Biotechnology Production, Revenue, Price Trend by Type

Chapter Six: Global Agricultural Biotechnology Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Agricultural Biotechnology Business

Chapter Eight: Agricultural Biotechnology Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Agricultural Biotechnology Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

The rest is here:
Impact Of Covid-19 on Agricultural Biotechnology Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Crypto Daily